557 related articles for article (PubMed ID: 33087933)
21. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
[TBL] [Abstract][Full Text] [Related]
23. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8
Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC
Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.
van den Bulk J; de Miranda NFCC; Ten Dijke P
Clin Sci (Lond); 2021 Jan; 135(1):35-52. PubMed ID: 33399850
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor-β1 signalling triggers vascular endothelial growth factor resistance and monocyte dysfunction in type 2 diabetes mellitus.
Makowski LM; Leffers M; Waltenberger J; Pardali E
J Cell Mol Med; 2021 Jun; 25(11):5316-5325. PubMed ID: 33942489
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction.
Bellinghausen I; König B; Böttcher I; Knop J; Saloga J
Clin Exp Allergy; 2006 Dec; 36(12):1546-55. PubMed ID: 17177678
[TBL] [Abstract][Full Text] [Related]
27. IL-4 together with IL-1β induces antitumor Th9 cell differentiation in the absence of TGF-β signaling.
Xue G; Jin G; Fang J; Lu Y
Nat Commun; 2019 Mar; 10(1):1376. PubMed ID: 30914642
[TBL] [Abstract][Full Text] [Related]
28. Essential role of TGF-beta in the natural resistance to experimental allergic encephalomyelitis in rats.
Cautain B; Damoiseaux J; Bernard I; van Straaten H; van Breda Vriesman P; Boneu B; Druet P; Saoudi A
Eur J Immunol; 2001 Apr; 31(4):1132-40. PubMed ID: 11298338
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
Fujita T; Teramoto K; Ozaki Y; Hanaoka J; Tezuka N; Itoh Y; Asai T; Fujino S; Kontani K; Ogasawara K
Cancer Res; 2009 Jun; 69(12):5142-50. PubMed ID: 19491278
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
[TBL] [Abstract][Full Text] [Related]
32. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis.
Qin Q; Chang Y; Wang D; Wu Y; Zhang LL; Wei W
Int Immunopharmacol; 2011 Dec; 11(12):2167-75. PubMed ID: 21996540
[TBL] [Abstract][Full Text] [Related]
33. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness.
Piccirillo CA; Letterio JJ; Thornton AM; McHugh RS; Mamura M; Mizuhara H; Shevach EM
J Exp Med; 2002 Jul; 196(2):237-46. PubMed ID: 12119348
[TBL] [Abstract][Full Text] [Related]
34. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
[TBL] [Abstract][Full Text] [Related]
35. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis.
Inobe J; Slavin AJ; Komagata Y; Chen Y; Liu L; Weiner HL
Eur J Immunol; 1998 Sep; 28(9):2780-90. PubMed ID: 9754565
[TBL] [Abstract][Full Text] [Related]
36. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.
Jiao S; Subudhi SK; Aparicio A; Ge Z; Guan B; Miura Y; Sharma P
Cell; 2019 Nov; 179(5):1177-1190.e13. PubMed ID: 31730856
[TBL] [Abstract][Full Text] [Related]
37. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
[TBL] [Abstract][Full Text] [Related]
38. TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.
Angelov SN; Hu JH; Wei H; Airhart N; Shi M; Dichek DA
Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):2102-2113. PubMed ID: 28729364
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
Seo N; Hayakawa S; Takigawa M; Tokura Y
Immunology; 2001 Aug; 103(4):449-57. PubMed ID: 11529935
[TBL] [Abstract][Full Text] [Related]
40. CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.
Alotaibi FM; Min WP; Koropatnick J
Front Immunol; 2024; 15():1256766. PubMed ID: 38487537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
